Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy
Genotype can refine risk stratification and inform clinical management in HCM. Sarcomeric HCM is associated with worse prognosis and may benefit from more vigilant surveillance for arrhythmias and systolic dysfunction, with a lower threshold for advanced therapies. Comorbidities, including hypertension and obesity, may be modifiable risk factors for patients with nonsarcomeric HCM.
Authors
- John C. Stendahl (ORCID: https://orcid.org/0000-0002-1568-9280)
- Christoffer Rasmus Vissing (ORCID: https://orcid.org/0000-0002-0834-206X)
- Dominic James Abrams (ORCID: https://orcid.org/0000-0001-5266-2805)
- J. Anthony Ware
- H Bundgaard
- A A R Axelsson Raja
- S Saberi
- M Michels
- Sharlene M. Day
- Rachel Lampert
- Thomas D. Ryan
- Belinda Gray
- Victoria N. Parikh
- Carolyn Y. Ho
- Joseph W. Rossano
- Anjali T. Owens
- Adam S. Helms
- Brian L. Claggett
- Neal K. Lakdawala
- Lia Crotti
- Jodie Ingles
- Iacopo Olivotto
Institutions
- Brigham and Women's Hospital (US)
- Cincinnati Children's Hospital Medical Center (US)
- Boston Children's Hospital (US)
- Garvan Institute of Medical Research (AU)
- Cardiovascular Institute of the South (US)
- University of Michigan (US)
- Royal Prince Alfred Hospital (AU)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- Hvidovre Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Harefield Hospital (GB)
- Yale University (US)
- Meyer Children's Hospital (IT)
- Michigan Medicine (US)
- IRCCS Istituto Auxologico Italiano (IT)
- Thorax Foundation (GR)
- University of Milano-Bicocca (IT)
- University of Pennsylvania (US)
- Erasmus University Rotterdam (NL)
- Stanford University (US)
Publication Details
- Journal
- Circulation
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1161/circulationaha.125.076036
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00